Economic Evaluation of Nivolumab Versus Docetaxel for the Treatment of Advanced Squamous and Non-squamous Non-small Cell Lung Cancer After Prior Chemotherapy in China-Reference-Cited by-同舟云学术

Economic Evaluation of Nivolumab Versus Docetaxel for the Treatment of Advanced Squamous and Non-squamous Non-small Cell Lung Cancer After Prior Chemotherapy in China

Published:2023-03 Issue:2 Volume:7 Page:273-284
ISSN:2509-4262
Container-title:PharmacoEconomics - Open
language:en
Short-container-title:PharmacoEconomics Open

Author:

Hu Shanlian,Tang Zhiliu,Harrison James P.,Hertel Nadine,Penrod John R.,May Jessica R.,Juarez-Garcia Ariadna,Holdgate Orban

Funder

bristol-myers squibb

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Health Policy,Pharmacology

Link

https://link.springer.com/content/pdf/10.1007/s41669-022-00383-x.pdf

Reference63 articles.

1. International Agency for Research on Cancer. Cancer today. Data visualization tools for exploring the global cancer burden in 2018. http://gco.iarc.fr/today/home. Accessed 7 Dec 2018.

2. American Cancer Society. What is non-small cell lung cancer? https://www.cancer.org/cancer/non-small-cell-lung-cancer/about/what-is-non-small-cell-lung-cancer.html. Accessed 7 Dec 2018.

3. National Cancer Institute Surveillance Epidemiology and End Results. Cancer stat facts: lung and bronchus cancer. https://seer.cancer.gov/statfacts/html/lungb.html. Accessed 31 May 2019.

4. Chouaid C, Agulnik J, Goker E, et al. Health-related quality of life and utility in patients with advanced non-small-cell lung cancer: a prospective cross-sectional patient survey in a real-world setting. J Thorac Oncol. 2013;8(8):997–1003.

5. Hechtner M, Eichler M, Wehler B, et al. Quality of life in NSCLC survivors—a multicenter cross-sectional study. J Thorac Oncol. 2019;14(3):420–35.